ESMO: Merck & Co Vibostolimab Data Are Another Validation Of TIGIT

Shows Promise Alone And In Keytruda Combo

A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.

Race_Cars_Children
Merck And Roche Jostling For Position In TIGIT Race • Source: Shutterstock

Merck & Co., Inc. is hoping to be at the head of the TIGIT field, seen by many as the most promising class in the new wave of immuno-oncology products and currently led by Roche Holding AG's tiragolumab, and early stage data on its candidate, vibostolimab, while limited, look promising.

The drug giant presented two abstracts from a Phase Ib trial at the virtual European Society for Medical Oncology congress,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer